OBJECTIVE: To independently confirm previous probe drug findings that patients with rheumatoid arthritis (RA) have defective oxidation of cysteine derivatives. METHODS: Measurement of cysteine dioxygenase substrate (cysteine) and product (sulfate) under controlled conditions, with elemental assessment by proton induced x-ray emission (PIXE). RESULTS: Plasma inorganic sulfate was significantly depressed in patients with rheumatoid arthritis (RA) compared to both controls and non-RA disease, 85 +/- 36 nm/ml vs 267 +/- 146 and 604 +/- 412 (mean +/- SD. RA patients vs non-RA disease p < 0.001). Fasting cysteine levels were significantly raised compared to controls (59 +/- 20 nm/ml vs 17 +/- 81 nm/ml p < 0.001). Synovial fluid (SF) sulfate was also significantly reduced in patients with RA compared to non-RA controls (202 +/- 117 nm vs 1041 +/- 700 p < 0.001). PIXE data confirmed the low sulfate levels in serum and SF while showing no reduction in the levels of other elements analyzed. CONCLUSIONS: These cysteine/sulfate findings confirm the validity of the previous probe drug abnormalities and the importance of defective cysteine dioxygenase activity in RA.
OBJECTIVE: To independently confirm previous probe drug findings that patients with rheumatoid arthritis (RA) have defective oxidation of cysteine derivatives. METHODS: Measurement of cysteine dioxygenase substrate (cysteine) and product (sulfate) under controlled conditions, with elemental assessment by proton induced x-ray emission (PIXE). RESULTS: Plasma inorganic sulfate was significantly depressed in patients with rheumatoid arthritis (RA) compared to both controls and non-RA disease, 85 +/- 36 nm/ml vs 267 +/- 146 and 604 +/- 412 (mean +/- SD. RA patients vs non-RA disease p < 0.001). Fasting cysteine levels were significantly raised compared to controls (59 +/- 20 nm/ml vs 17 +/- 81 nm/ml p < 0.001). Synovial fluid (SF) sulfate was also significantly reduced in patients with RA compared to non-RA controls (202 +/- 117 nm vs 1041 +/- 700 p < 0.001). PIXE data confirmed the low sulfate levels in serum and SF while showing no reduction in the levels of other elements analyzed. CONCLUSIONS: These cysteine/sulfate findings confirm the validity of the previous probe drug abnormalities and the importance of defective cysteine dioxygenase activity in RA.
Authors: Ivette A G Deckers; Leo J Schouten; Leander Van Neste; Iris J H van Vlodrop; Patricia M M B Soetekouw; Marcella M L L Baldewijns; Jana Jeschke; Nita Ahuja; James G Herman; Piet A van den Brandt; Manon van Engeland Journal: Clin Cancer Res Date: 2015-04-22 Impact factor: 12.531
Authors: Camden M Driggers; Richard B Cooley; Banumathi Sankaran; Lawrence L Hirschberger; Martha H Stipanuk; P Andrew Karplus Journal: J Mol Biol Date: 2013-06-07 Impact factor: 5.469
Authors: Iori Ueki; Heather B Roman; Alessandro Valli; Krista Fieselmann; Jimmy Lam; Rachel Peters; Lawrence L Hirschberger; Martha H Stipanuk Journal: Am J Physiol Endocrinol Metab Date: 2011-06-21 Impact factor: 4.310
Authors: Chad R Simmons; Kalyanaraman Krishnamoorthy; Spencer L Granett; David J Schuller; John E Dominy; Tadhg P Begley; Martha H Stipanuk; P Andrew Karplus Journal: Biochemistry Date: 2008-10-11 Impact factor: 3.162